These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27030005)

  • 41. Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial.
    Mentz RJ; Chung MJ; Gheorghiade M; Pang PS; Kwasny MJ; Ambrosy AP; Vaduganathan M; O'Connor CM; Swedberg K; Zannad F; Konstam MA; Maggioni AP
    Am Heart J; 2012 Dec; 164(6):884-92.e2. PubMed ID: 23194489
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure.
    Black-Maier E; Steinberg BA; Piccini JP
    Expert Rev Cardiovasc Ther; 2015 Jun; 13(6):627-36. PubMed ID: 25959096
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimization of heart rate lowering therapy in hospitalized patients with heart failure: Insights from the Optimize Heart Failure Care Program.
    Lopatin YM; Cowie MR; Grebennikova AA; Sisakian HS; Pagava ZM; Hayrapetyan HG; Abdullaev TA; Voronkov LG; Chesnikova AI; Tseluyko VI; Tarlovskaya EI; Dadashova GM; Berkinbaev SF; Glezer MG; Koziolova NA; Rakisheva AG; Kipiani ZV; Kurlyanskaya AK
    Int J Cardiol; 2018 Jun; 260():113-117. PubMed ID: 29622423
    [TBL] [Abstract][Full Text] [Related]  

  • 44. β-Blockade in Heart Failure With Reduced Ejection Fraction: Does Heart Rate Control Influence Readmissions?
    Owens RE; Twilla JD; Self TH; Alshaya AI; Metra CJ; Cummings C; Oliphant CS
    J Pharm Pract; 2018 Feb; 31(1):40-45. PubMed ID: 28737066
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association between resting heart rate, chronotropic index, and long-term outcomes in patients with heart failure receiving β-blocker therapy: data from the HF-ACTION trial.
    Dobre D; Zannad F; Keteyian SJ; Stevens SR; Rossignol P; Kitzman DW; Landzberg J; Howlett J; Kraus WE; Ellis SJ
    Eur Heart J; 2013 Aug; 34(29):2271-80. PubMed ID: 23315907
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey.
    Cohen Solal A; Leurs I; Assyag P; Beauvais F; Clerson P; Contre C; Thebaut JF; Genoun M;
    Arch Cardiovasc Dis; 2012; 105(6-7):355-65. PubMed ID: 22800720
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT).
    Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Tavazzi L
    Eur J Heart Fail; 2010 Jan; 12(1):75-81. PubMed ID: 19892778
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Does atrial fibrillation in elderly patients with chronic heart failure limit the efficacy of carvedilol? Suggestions from an observational study.
    Opasich C; De Feo S; Cioffi G; Pulignano G; Del Sindaco D; Tarantini L; Gualco A; Patrignani A
    Ital Heart J; 2005 Apr; 6(4):323-7. PubMed ID: 15902931
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction: a report from the CHART-2 Study.
    Takada T; Sakata Y; Miyata S; Takahashi J; Nochioka K; Miura M; Tadaki S; Shimokawa H;
    Eur J Heart Fail; 2014 Mar; 16(3):309-16. PubMed ID: 24464774
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of β-blockers on 1-year survival and hospitalizations in patients with heart failure and atrial fibrillation: results from ESC-HF Pilot and ESC-HF Long-Term Registry.
    Ozierański K; Kapłon-Cieślicka A; Balsam P; Tymińska A; Wancerz A; Peller M; Marchel M; Crespo-Leiro MG; Maggioni AP; Drożdż J; Filipiak KJ; Opolski G
    Pol Arch Intern Med; 2018 Nov; 128(11):649-657. PubMed ID: 30303491
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An Updated Review on the Role of Non-dihydropyridine Calcium Channel Blockers and Beta-blockers in Atrial Fibrillation and Acute Decompensated Heart Failure: Evidence and Gaps.
    Triska J; Tamargo J; Bozkurt B; Elkayam U; Taylor A; Birnbaum Y
    Cardiovasc Drugs Ther; 2023 Dec; 37(6):1205-1223. PubMed ID: 35357604
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ivabradine for the treatment of chronic heart failure.
    Henri C; O'Meara E; De Denus S; Elzir L; Tardif JC
    Expert Rev Cardiovasc Ther; 2016; 14(5):553-61. PubMed ID: 26967048
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Beta-blocker treatment of chronic systolic heart failure improves prognosis even in patients meeting one or more exclusion criteria of the MERIT-HF study.
    Jost A; Rauch B; Hochadel M; Winkler R; Schneider S; Jacobs M; Kilkowski C; Kilkowski A; Lorenz H; Muth K; Zugck C; Remppis A; Haass M; Senges J;
    Eur Heart J; 2005 Dec; 26(24):2689-97. PubMed ID: 16183697
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure).
    Fonarow GC; Abraham WT; Albert NM; Stough WG; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy CW; Young JB
    Am J Cardiol; 2008 Dec; 102(11):1524-9. PubMed ID: 19026308
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial.
    Komajda M; Tavazzi L; Francq BG; Böhm M; Borer JS; Ford I; Swedberg K;
    Eur J Heart Fail; 2015 Dec; 17(12):1294-301. PubMed ID: 26377342
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis.
    Hartmann C; Bosch NL; de Aragão Miguita L; Tierie E; Zytinski L; Baena CP
    Int J Clin Pharm; 2018 Dec; 40(6):1443-1453. PubMed ID: 30173307
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study).
    Borer JS; Böhm M; Ford I; Robertson M; Komajda M; Tavazzi L; Swedberg K;
    Am J Cardiol; 2014 Feb; 113(3):497-503. PubMed ID: 24332674
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ivabradine, a novel medication for treatment of heart failure with reduced ejection fraction.
    Foster JL; Bobadilla RV
    J Am Assoc Nurse Pract; 2016 Nov; 28(11):576-582. PubMed ID: 27215699
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Permanent atrial fibrillation affects exercise capacity in chronic heart failure patients.
    Agostoni P; Emdin M; Corrà U; Veglia F; Magrì D; Tedesco CC; Berton E; Passino C; Bertella E; Re F; Mezzani A; Belardinelli R; Colombo C; La Gioia R; Vicenzi M; Giannoni A; Scrutinio D; Giannuzzi P; Tondo C; Di Lenarda A; Sinagra G; Piepoli MF; Guazzi M
    Eur Heart J; 2008 Oct; 29(19):2367-72. PubMed ID: 18682448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.